Omega Diagnostics (RVKA) Stock Price & Analysis
RVKA Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.01
- 52-Week Range
- EUR 0.01 - EUR 0.03
- Previous Close
- EUR 0.01
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 4.41M
- Enterprise Value
- EUR 1.89M
- Total Cash (Recent Filing)
- EUR 2.64M
- Total Debt (Recent Filing)
- EUR 125.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.59
- Next Earnings
- Nov 19, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces financial risk and limits the burden of interest and refinancing costs. It also preserves flexibility to support operations, invest in diagnostic products, or manage periods of weak earnings without the constraints associated with a heavily indebted balance sheet.
Solid Gross Margins
The consistently solid gross-margin structure indicates that the company’s diagnostic products can generate meaningful value above direct costs. If revenue stabilizes, this provides a foundation for operating leverage and gives management scope to rebuild profitability without needing a fundamental change in the product model.
Established IVD Platform
Operating across development, manufacturing, and supply of in-vitro diagnostic products gives Omega an established platform in a healthcare testing market. Its combination of rapid assays, laboratory formats, reagents, and components supports multiple product pathways rather than reliance on a single diagnostic format.
Bears Say
Revenue Contraction
The recent revenue pattern is volatile and currently negative, with contraction following the 2024 rebound. Sustained top-line weakness can reduce manufacturing efficiency, dilute fixed-cost absorption, and make it harder for the company to convert its solid gross-margin structure into dependable operating and net profits.
Severe Earnings Volatility
The sharp reversal from strong 2025 profitability to heavy 2026 losses shows that earnings are not yet dependable. Such volatility weakens confidence in near-term earnings power, can erode equity through recurring losses, and makes internal funding for product development or growth less reliable.
Recurring Cash Burn
Renewed operating and free-cash-flow losses indicate that reported gross margins are not currently translating into cash generation. Persistent burn can restrict reinvestment, increase reliance on available funding, and reduce resilience if weak revenue or losses continue over the next several quarters.
Omega Diagnostics News
RVKA FAQ
What was Omega Diagnostics’s price range in the past 12 months?
What is Omega Diagnostics’s market cap?
When is Omega Diagnostics’s upcoming earnings report date?
How were Omega Diagnostics’s earnings last quarter?
Is Omega Diagnostics overvalued?
Does Omega Diagnostics pay dividends?
What is Omega Diagnostics’s EPS estimate?
How many shares outstanding does Omega Diagnostics have?
What happened to Omega Diagnostics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Omega Diagnostics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Omega Diagnostics
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- James Cooper
- Employees
- 85
- Website
- www.cnsplc.com
- Address
- One Fleet Place, London, GL, EC4M 7WS, GB
Omega Diagnostics (RVKA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |